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Exo-Functionalized Metallacages as
Host-Guest Systems for the
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and Angela Casini*
School of Chemistry, Cardiff University, Cardiff, United Kingdom
Within the framework of designing new self-assembled metallosupramolecular
architectures for drug delivery, seven [Pd2L4]
4+ metallacages (L = 2,6-bis(pyridine-3-yl
ethynyl)pyridine) featuring different groups in exo-position, selected to enhance the cage
solubility in aqueous environment, were synthesized. Thus, carboxylic acids, sugars, and
PEG groupswere tethered to the bispyridyl ligands directly or via disulfide bond formation,
as well as via click chemistry. The ligands and respective cages were characterized by
different methods, including NMR spectroscopy and high-resolution electrospray mass
spectrometry (HR-ESI-MS). While the two ligands featuring carboxylic acid-functionalized
groups showed improved solubility in water, the other ligands were soluble only in organic
solvents. Unfortunately, all the respective self-assembled cages were also insoluble
in water. Afterwards, the encapsulation properties of the anticancer drug cisplatin in
selected [Pd2L4]X4 cages (X=NO
−
3 , BF
−
4 ) were studied by
1H, 1H DOSY, and 195Pt NMR
spectroscopy. The effect of the counter ions as well as of the polarity of the solvent in
the drug encapsulation process were also investigated, and provided useful information
on the host-guest properties of these experimental drug delivery systems. Our results
provide further experimental support for previous studies that suggest the desolvation
of guests from surrounding solvent molecules and the resulting solvent rearrangement
may actually be the primary driving force for determining guest binding affinities in
metallacages, in the absence of specific functional group interactions.
Keywords: metallacages, supramolecular coordination complexes, water solubility, host-guest chemistry,
cisplatin
INTRODUCTION
Supramolecular chemistry has its roots in biology, and in recent years the unique and often
advantageous properties of supramolecular materials have led to their extensive exploration in the
fields of biomolecular recognition, drug delivery, disease diagnosis, and imaging. In this context,
supramolecular coordination complexes (SCCs) hold great promise (Cook et al., 2013; Casini
et al., 2017). In fact, the number of reports on the bioactivity of three-dimensional (3D) SCCs
with different shapes has substantially increased (Kaner et al., 2016; Preston et al., 2016; Casini
et al., 2017) and includes helicates (Schmitt et al., 2012), metallacages (Vajpayee et al., 2011),
cubes (Ahmedova et al., 2016), prisms(Ahmad et al., 2015), and capsules (Therrien, 2013). These
systems are of general formula MnLm, where M is usually Fe(II), Pd(II), Pt(II), or half-sandwich
organometallic clips based on Ru(II), Os(II), or Ir(III) and Rh(III), and L is the ligand of the
coordination complex.
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In 2012, Lewis et al. reported on the encapsulation properties
of the anticancer drug cisplatin within cationic [Pd2L4]
4+
cages (L= 2,6-bis(pyridine-3-ylethynyl)pyridine as the bidentate
ligand) studied by NMR and X-ray diffraction analysis (Lewis
et al., 2012). Following these promising results, as part of
our efforts to develop functional metallosupramolecular drug
delivery vectors, we have recently expanded the family of exo-
functionalized [Pd2L4]
4+ cages coupled to fluorescent groups
for imaging by fluorescence microscopy (Kaiser et al., 2016;
Schmidt et al., 2016a,b), as well as to peptides for targeted
drug delivery of cisplatin to cancer cells (Han et al., 2017,
2018). It is worth mentioning that while cisplatin occupies
a crucial role in the treatment of various malignant tumors,
its efficacy, and applicability are heavily restricted by severe
systemic toxicities and drug resistance. Thus, our recent
studies have exploited the host-guest properties of targeted
metallacages to enhance the activity of cisplatin in cancer cells,
protecting it from metabolism (Han et al., 2017). Of note, the
reduced toxicity of cisplatin encapsulated in integrin targeted
metallacages has also been demonstrated by us in an ex vivo
model (Han et al., 2017).
As the initially developed cage architectures displayed
scarce water solubility, we were interested in improving
their hydrophilicity via derivatization of the ligand scaffold.
Thus, here, a small library of bis(pyridyl) ligands—of general
scaffold 3,5-bis(3-ethynylpyridine)phenyl (Scheme 1) - exo-
functionalized with chemical groups envisioned to improve
the aqueous solubility, were synthesized and self-assembled
into the corresponding [Pd2L4]
4+ cages. The products
were characterized by NMR, HR-ESI-MS, and IR. The
solubility of the resulting metallacages was then tested in
water, as well as in a range of common organic solvents.
Furthermore, in order to elucidate the host-guest chemistry of
the metallacages and the factors that favor cisplatin’s retention
in the supramolecular complexes, essential aspects to exploit
the cages as drug delivery systems, the drug encapsulation was
studied by 1H, 1H DOSY, and 195Pt NMR spectroscopy under
different conditions.
RESULTS AND DISCUSSION
Adapting previously reported procedures (Schmidt et al.,
2016b), the synthesis of the exo-functionalized ligand scaffold
with carboxylic acid groups, L1, and L2 was first achieved
by Sonogashira cross-coupling of a benzyl-protected 1,3-
dibromophenyl precursor with 3-ethynylpyridine, followed by
basic deprotection of the benzyl ester to afford the free acid,
forming the highly conjugated bispyridyl ligand scaffold in good
yields (Scheme S1). A polyethylene glycol exo-functionalized
ligand (L3) was also synthesized. In this case, a ligand
bearing a central phenol aromatic ring was synthesized via
Sonogashira cross-coupling, which was then was coupled to
1-chloro-2-(2-methoxyethoxy) ethane under basic conditions
to achieve ligand L3 (Scheme S2). In addition, ligands L4
and L5, featuring water-soluble thio-β-D-glucose moieties,
were synthesized for the first time. This was achieved by
first synthesizing an alkyl bromide exo-functionalized ligand
via classic Appel reaction using triphenylphosphine, carbon
tetrabromide, and 3,5-bis(3-ethynylpyridine)-benzylalcohol; the
latter having been synthesized via Sonogashira cross-coupling
(Scheme S3). The 1-thio-β-D-glucose tetraacetate group was
then conjugated under basic conditions following a SN2 type
reaction to afford the ligand L4. Ligand L5 was achieved
by deacetylation of L4 using Amberlite-IRA 401 (OH−)
ion exchange beads, which were stirred together at room
temperature overnight, following previously reported procedures
(Lewis et al., 2014). Finally, the ligands L6 and L7 were
synthesized using standard CuAAC “Click” reaction conditions
(Scheme S4) following similar procedures reported for analogous
tris-pyridyl ligand scaffolds (Lewis et al., 2013). Noteworthy,
the latter were reported to be soluble in water, and therefore,
offered a logical starting point for functionalization of the
herein selected 3,5-bis(3-ethynylpyridine) phenyl ligands. All the
ligands were characterized by NMR (1H, 13C) and HR-ESI-MS.
A summary of the synthesized ligands and cages can be found
in Scheme S5.
The solubility of the ligands in water was assessed by overnight
sonication in D2O (10 mg/mL, 20
◦C), before filtration (pore size
450µm). The filtrate was analyzed by 1H NMR to determine
if detectable amounts of ligand were present. Unfortunately,
the exo-functionalized bispyridyl ligand scaffolds were found to
be scarcely soluble, and were all undetectable in D2O solution,
except for the carboxylic acid functionalized ligands (L1 = 10
mg/mL, L2 > 100 mg/mL). The latter could be analyzed by
1H NMR in D2O (data not shown).
Afterwards, [Pd2L4]
4+ cage formation was achieved via
self-assembly by reacting two equivalents of Pd(II) nitrate
pentahydrate with four equivalents of the functionalized
ligand (L1-L7) in DMSO at room temperature, to form the
corresponding homoleptic metallacages (C1-C7) (Scheme 1).
The products were analyzed by NMR (1H, 13C, 11B, and
19F), HR-ESI-MS (Figures S1–S3, S5–S9) and IR. Following
previously reported examples (Schmidt et al., 2016c),
quantitative cage formation was monitored by 1H NMR,
whereby the peaks corresponding to the protons alpha to
the coordinating nitrogen of the terminal pyridine rings of
the ligand undergo a large downfield shift, attributable to
the withdrawal of electron density from the aromatic system
following coordination to palladium (added in stoichiometric
amounts). A representative 1H NMR spectra for cage C2
formation is shown in Figure S4.
In order to assess whether the synthesized metallacages were
soluble in water, the products were suspended in D2O (8mg
per mL) and sonicated at 37◦C for 24 h. The fine suspension
was then filtered, and the filtrate was analyzed by 1H NMR.
Despite the tetra-cationic nature of the metallacages, and the
incorporation of solubilizing entities to the ligand scaffold, none
of the metallacages (C1-C7) were soluble in D2O. In fact, the
filtrate solutionwas colorless and no trace of a proton signal could
be found in the 1H NMR spectra.
As a second attempt to water solubilization, and taking
inspiration from previous work by Altmann and Pöthig (2016)
on the synthesis of water soluble Ag(I) and Au(I) pillarplexes,
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SCHEME 1 | Top: General scheme for [Pd2L4]
4+ metallacage formation via self-assembly. Bottom: Numbered (n) chemical structures of the exo-functionalized
groups envisioned to improve the cages’ aqueous solubility.
we synthesized new cages featuring acetate as the counterion
by the use of palladium(II) acetate as the precursor in the
self-assembly. However, this attempt produced an insoluble
residue that could not be dissolved in either organic solvents
or water.
Concerning cisplatin encapsulation, in the case of
previously reported [Pd2L4]BF4 cages (L = (2,6-bis(pyridin-3-
ylethynyl)pyridine)) it was hypothesized that their central cavities
are lined with four hydrogen bond accepting pyridine units
which enable the encapsulation of two cisplatin molecules within
the metallosupramolecular architecture through hydrogen
bonding interactions between the cage and the amine ligands
of the cisplatin guest (Lewis et al., 2012). This idea has been
supported by NMR spectroscopy studies (Lewis et al., 2012),
where chemical shifts of hydrogens in the trispyridyl ligands were
observed upon cisplatin encapsulation. Control experiments
confirm the importance of the hydrogen bonding interaction
between the cage and the amine ligands of the cisplatin guest.
It was also observed that upon addition of small amounts of
D2O to a solution of the cisplatin-cage host-guest adduct in
acetonitrile, the Ha, and Hb proton signals of the cage sharpen
and shift upfield again, indicating evacuation of cisplatin from
the cavity (Lewis et al., 2012).
In this context, information on the encapsulation process of
cisplatin within the more hydrophobic cavity of the bispydridyl
ligand forming our [Pd2L4]
4+ cages, as opposed to the less
hydrophobic cavity of trispyridyl-ligand Pd2L4 metallacages
(Lewis et al., 2012, 2014), needs to be achieved still. Thus, we
investigated if the encapsulation of the anticancer drug cisplatin
could occur in the metallacages using 1H NMR spectroscopy.
In order to avoid DMSO as the solvent, since it is known
to exchange cisplatin’s chlorido ligands, the experiment was
carried out in DMF-d7. Cage C1 [Pd2L4](NO3)4 was selected
to study the encapsulation process due to its solubility in this
solvent. Figure 1 shows the variation of the chemical shifts of
selected cage protons upon cisplatin encapsulation. Specifically,
we could clearly observe the chemical shifts of peaks Ha and
Hb: the peak of Ha, a cavity-facing proton, showed a small
upfield shift of δ −1.0Hz. The exo-facing proton, Hb, showed a
downfield shift upon cisplatin encapsulation, in accordance with
previously reported studies (Lewis et al., 2012). Unfortunately,
the cavity facing peak He, likely to interact with the guest Pt(II)
complex, was masked by the peak of Hf, and therefore, could not
be analyzed.
It is worth mentioning that the observed smaller chemical
shifts of the cavity facing proton Ha, with respect to those
reported by Lewis et al. (2012) can be due to the lack of the
H-bonding with the cisplatin guest (via N—H3N). Moreover,
it has been previously reported that NO−3 counterions are
encapsulated within the cage architecture of trispyridyl Pd2L4
metallacages featuring a nitrogen in endo-position, while BF−4
ions are not (Lewis and Crowley, 2014). Thus, we hypothesized
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FIGURE 1 | Cisplatin encapsulation in a metallacage following displacement of nitrate ions from the cavity. Stacked spectra of cage C1 in DMF-d7 (top) and cage C1
after the addition of 2 equation of cisplatin (bottom). Box: Zoom-in of signals for peaks Ha and Hb with chemical shifts of δ = −0.002 ppm (upfield) and +0.01 ppm
(downfield), respectively.
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that the observed small chemical shift of Ha following cisplatin
encapsulation was due to the presence of NO−3 ions inside the
cage, which already induced chemical shifts of Ha and Hb and
thus, acted to “mask” the effect of the cisplatin encapsulation
process. In fact, upon evacuation of the anionic NO−3 counterion,
the “de-shielding” effect of the cavity facing protons from NO−3
would be reduced as the neutral guest, cisplatin, occupies the
metallacage cavity.
Afterwards, we also investigated if cisplatin would
preferentially be encapsulated within our bispyridyl type
Pd2L4 metallacages featuring a different counter ion. Therefore,
an analogous metallacage was synthesized with BF−4 as the
counterion, C1.BF4 and studied for its cisplatin encapsulation
properties by 1H NMR spectroscopy. Supporting Figure S10
shows the stacked 1H NMR spectrum of C1.BF4, alone or
encapsulating cisplatin [C1.BF4⊂(cisplatin)] in DMF-d7.
Indeed, both Ha and Hb show marked downfield shifts upon
cisplatin encapsulation of 0.044 and 0.033 ppm, respectively.
In addition, He also shows a downfield shift of 0.03 ppm.
Furthermore, the peaks of both Ha and Hb ofC1 (before addition
of cisplatin) are already shifted further downfield (Figure 1,
ca. 0.095 and 0.001 ppm, respectively) when compared to Ha
and Hb of C1.BF4 (Figure S10) consistent with encapsulation
of NO−3 .
To continue our investigation, the effect of the solvent
polarity was hypothesized to be the driving force of the cisplatin
encapsulation process. Thus, the latter was also tested using
C1.BF4 in MeCN-d3, with reduced polarity with respect to
DMF-d7. However, upon addition of 2 eq. cisplatin to the
MeCN-d3 solution of C1.BF4 (1 equation) a precipitate was
formed, even after several hours of sonication. The suspension
was filtered, and the resulting solution was analyzed by 1H
NMR spectroscopy. However, the resulting spectra showed no
indication of cisplatin encapsulation (data not shown). Instead,
the large upfield shift of the peaks corresponding to the α-
protons of the coordinating pyridyl is indicative of the ligands
no longer coordinated to Pd(II) ions. Moreover, the NMR
spectrum suggests that the structure of the ligand has also
been altered.
Therefore, in order to study the effects of the solvent on
cisplatin encapsulation, we synthesized a derivative of cage
C1.BF4, but where the carboxylic function was protected
by a benzyl group, namely cage C1Bn.BF4. Thus, cisplatin
encapsulation was followed by 1H NMR in MeCN-d3 and the
results are presented in Figure S11. As it can be observed, no
chemical shifts could be seen for any of the cage’s proton peaks
even after 24 h incubation of cisplatin at room temperature. We
could conclude that in acetonitrile, cisplatin encapsulation is
not favored. In order to check that metallodrug encapsulation
was not prevented by the presence of the benzyl group on the
cage, we also monitored the process once more in DMF-d7.
The results are depicted in Figure S12 and indicate that, in
these conditions, cisplatin encapsulation occurs, as shown by
the chemical shifts of Ha (downfield, δ = +0.009 ppm), Hb
(downfield, δ = +0.021 ppm), and a small shift for the cavity-
facing proton He (upfield, δ = −0.002 ppm). The encapsulation
of cisplatin in cage C1Bn.BF4 was further studied in DMF-d7
using 195Pt NMR to see if a complementary shift could be
observed for the guest cisplatin molecules. Indeed, an upfield
shift of −5 ppm was observed upon addition of either 1 eq.
or 2 eq. of cisplatin in the presence of metallacage C1Bn.BF4
(Figure S13), supporting cisplatin encapsulation. The obtained
results are in agreement with previously reported ones from our
group on similar cage systems exo-functionalized with different
type of ligands (Schmidt et al., 2016c), indicating that surface
functionalization does not prevent the guest from entering
the cavity.
The encapsulation of cisplatin in C1Bn.BF4 was also studied
by 1H DOSY NMR in DMF-d7. Cisplatin alone shows a broad
signal at 4.18 ppm, HNH3 with a diffusion coefficient = −8.9
× 10−10 m2/s (Figure S14, red traces). Clear quenching of
this signal was observed upon addition of 1 eq. of metallacage
C1Bn.BF4 (Figure S14, blue traces). The cisplatin peak reappears
slightly upon addition of a second equivalent of cisplatin to
C1Bn.BF4⊂(cisplatin) (Figure S14, black traces), which may
suggest that the metallacage cavity has been saturated to form
C1Bn.BF4⊂(cisplatin)2 and residual cisplatin remains free in
solution, or that upon addition of a second equivalent of cisplatin,
a dynamic equilibrium occurs.
CONCLUSIONS
In conclusion, we report here on a series of exo-functionalized
[Pd2L4]
4+metallacages featuring bispydridyl ligands. Despite the
addition of hydrophilic groups to the ligands’ scaffold, or the use
of different counter ions, the increase in water solubility of the
resulting cages was not achieved. Thus, different strategies are
necessary to address this problem, including the conjugation of
the ligands to peptides. The latter approach has already proved to
be successful (Han et al., 2017).
Furthermore, the encapsulation of the anticancer drug
cisplatin in selected cages has been studied byNMR spectroscopy,
and the obtained results show that if the solvent is of
sufficient polarity, metallodrug encapsulation can easily occur
in the hydrophobic cavity of the cage despite the absence
of hydrogen-bond accepting central pyridine units (Lewis and
Crowley, 2014). Conversely, polar solvent molecules capable of
forming hydrogen-bond networks (including DMF and water)
are likely to prefer not to be encapsulated by hydrophobic
cage cavities, as in our case, and will not compete with the
cisplatin molecules. This hypothesis is corroborated by previous
studies on M4L6 metallacages for which guest encapsulation
in polar protic solvents, such as water, appears to be
driven by initial desolvation of the guest with concomitant
rearrangement of the hydrogen bond networks in solution,
more than by host-guest interactions alone (Leung et al.,
2008). In general, energetically favorable solvent rearrangement
during guest desolvation also explains the ability of the
supramolecular host to encapsulate neutral guests such as
cisplatin, in spite of the lack of possible electrostatic attraction
or H-bond interactions with the charged host, as in our
case. Further studies are ongoing in our lab to validate
this hypothesis.
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